We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...

Novo Nordisk A/S (NYSE:NVO) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks.

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

In December, Novo Nordisk reported that CagriSema was able to muster a 22.7% weight loss at 68 weeks in REDEFINE 1, which also fell short of its hoped-for reduction of 25%.

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Novo Nordisk shares fell due to a supply issue in the US, disappointing trial results for its new weight loss drug CagriSema, and heightened competition. The trust declared an interim dividend of 1.4p ...